Cargando…

Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer

SIMPLE SUMMARY: Unfortunately, not all patients with urothelial cancer benefit from checkpoint inhibitors (ICIs). Currently, the first radiological response evaluation is not performed until after 9 to 12 weeks of ICI therapy. Early response biomarkers might enable an early switch to more effective...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Wilpe, Sandra, Wosika, Victoria, Ciarloni, Laura, Hosseinian Ehrensberger, Sahar, Jeitziner, Rachel, Angelino, Paolo, Duiveman-de Boer, Tjitske, Koornstra, Rutger H. T., de Vries, I. Jolanda M., Gerritsen, Winald R., Schalken, Jack, Mehra, Niven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465885/ https://www.ncbi.nlm.nih.gov/pubmed/34572887 http://dx.doi.org/10.3390/cancers13184660

Ejemplares similares

Lactate dehydrogenase: a marker of diminished antitumor immunity
por: Van Wilpe, Sandra, et al.
Publicado: (2020)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder
por: van Wilpe, Sandra, et al.
Publicado: (2020)

Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma
por: Boudewijns, Steve, et al.
Publicado: (2014)

Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma
por: Tolmeijer, Sofie H., et al.
Publicado: (2021)

Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
por: van Wilpe, Sandra, et al.
Publicado: (2022)

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Creemers, Jeroen H. A., et al.
Publicado: (2021)

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
por: Tel, Jurjen, et al.
Publicado: (2016)

Eradicating cancer cells: struggle with a chameleon
por: Di, Jiabo, et al.
Publicado: (2011)

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination
por: Wimmers, Florian, et al.
Publicado: (2015)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites
por: Wefers, Christina, et al.
Publicado: (2019)

Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System
por: Wefers, Christina, et al.
Publicado: (2018)

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer
por: Smits, Minke, et al.
Publicado: (2020)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Discovery of a 29-Gene Panel in Peripheral Blood Mononuclear Cells for the Detection of Colorectal Cancer and Adenomas Using High Throughput Real-Time PCR
por: Ciarloni, Laura, et al.
Publicado: (2015)

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study
por: Knapen, Lotte M., et al.
Publicado: (2018)

Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2022)

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2021)

Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients
por: Bloemendal, Martine, et al.
Publicado: (2021)

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
por: van Willigen, Wouter W., et al.
Publicado: (2020)

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
por: van Willigen, Wouter W., et al.
Publicado: (2018)

Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death
por: Di Blasio, Stefania, et al.
Publicado: (2016)

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
por: Lubberman, Floor J. E., et al.
Publicado: (2019)

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
por: van der Doelen, Maarten J., et al.
Publicado: (2021)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

Functional OCT4-specific CD4(+) and CD8(+) T cells in healthy controls and ovarian cancer patients
por: Di, Jiabo, et al.
Publicado: (2013)

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue
por: Prinsen, Hetty, et al.
Publicado: (2015)

Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy
por: Gerritsen, Winald R., et al.
Publicado: (2011)

Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
por: Westdorp, Harm, et al.
Publicado: (2014)

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2020)

The Androgen Regulated lncRNA NAALADL2-AS2 Promotes Tumor Cell Survival in Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2022)

Single-particle imaging of stress-promoters induction reveals the interplay between MAPK signaling, chromatin and transcription factors
por: Wosika, Victoria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ba52nl8o3h39h0gb8dsg31q5kv